| Literature DB >> 20471252 |
Haiyan Cai1, Guirui Yan, Xiaodong Zhang, Olena Gorbenko, Heyao Wang, Weiliang Zhu.
Abstract
In this study, a series of small molecule inhibitors of human FABP4 were identified through virtual screening. Compound 1 is the most potent hit against FABP4 with a selectivity of more than 144-fold preferences over human FABP3. In addition, MD simulation and mutation studies revealed key residues for inhibitory potency and selectivity, which provides a guideline for further drug design against obesity, diabetes and atherosclerosis. Copyright 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20471252 DOI： 10.1016/j.bmcl.2010.04.095
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN： 0960-894X Impact factor: 2.823